Take a deep breath and re-read the first post. Of course earnings drive prices, the price of a stock is the net present value of the discounted stream of future earnings. That was not the point, nor did I suggest pent up demand. My point is something that is undeniable. Many institutional investors, including most importantly those that are considering taking a position in this stock, are reluctant to invest in stocks which are characterized as "roach motels" (you can get in but you can't get out) because of a small trading float. There are definite,undeniable benefits to increasing the float of this company, it has suffered from significant volatility caused simply because there is not enough stock to buy or use to cover a short. Irf and when the FDA comes out the right way on the medical device issue, there will be a short squeeze in this stock like you have never seen.
The shorts on this board know that, and are particularly frightened.